Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-HCC: atezolizumab + bevacizumab versus TACE in intermediate-stage hepatocellular carcinoma
jRCT2051210125Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Roche. Primary endpoint: Time to failure of treatment strategy. Started Nov 2021; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2051210125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210125.